Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis
Imatinib mesilate is a well-known antitumor target inhibitor of protein tyrosine kinase, which is effective in different cancer types expressing Bcr / Abl and, in particular, in hemoblastosis. A higher interest to imatinib during the COVID-19 epidemic is explained by the fact that cancer patients ar...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-01-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/300 |
| _version_ | 1826559138445918208 |
|---|---|
| author | I. N. Mikhaylova N. M. Treshalina I. Zh. Shubina I. V. Manina M. V. Kiselevsky A. N. Lukashev |
| author_facet | I. N. Mikhaylova N. M. Treshalina I. Zh. Shubina I. V. Manina M. V. Kiselevsky A. N. Lukashev |
| author_sort | I. N. Mikhaylova |
| collection | DOAJ |
| description | Imatinib mesilate is a well-known antitumor target inhibitor of protein tyrosine kinase, which is effective in different cancer types expressing Bcr / Abl and, in particular, in hemoblastosis. A higher interest to imatinib during the COVID-19 epidemic is explained by the fact that cancer patients are one of the COVID-19 risk groups. Moreover, imatinib target mechanism of action, which is effective in cancer, can have a high potential against the most severe COVID-19 complication such as the disease associated pulmonary fibrosis. COVID-19 associated interstitial pulmonary fibrosis develops as an autoimmune process caused by systemic inflammation with atypical (idiopathic) pneumonia resulting from acute respiratory distress syndrome with the tyrosine kinase mechanism of signaling pathway activation and cellular response. Experi-mental and clinical results showing antifibrotic and dose-related antithrombotic imatinib effect demonstrate perspective use of this antitumor agent to correct COVID-19 associated pneumonia causing a high death rate of patients with COVID-19.The review presents literature data of 2001–2020 discussing pathologic genetic and clinical characteristics of the fibrosis which exacerbates COVID-19 pneumonia in adults. The sequence of the disease processes demonstrates that disease progression with the decreasing oxygen saturation in the peripheral blood intensifies local thrombosis in the lungs. As a result, hypoxia is developing, which is difficult to control and can cause lethal outcome in severe cases. Yet, the conventional antifibrotic and thrombolytic agents can only partially control the process of pneumofibrosis including that of cancer patients. The approximate antifibrotic dose of imatinib 400 mg / day is therapeutic for oncopatho-logy. The antitumor drug registered in many countries and well described side effects and contraindications needs no long-term registration studies for a new indication, therefore, it may be easily prepared for clinical testing. |
| first_indexed | 2024-03-12T18:43:32Z |
| format | Article |
| id | doaj.art-2dec9836ae5f44699ec3bc727a43fc3c |
| institution | Directory Open Access Journal |
| issn | 2313-805X 2413-3787 |
| language | Russian |
| last_indexed | 2025-03-14T08:55:37Z |
| publishDate | 2021-01-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Успехи молекулярной онкологии |
| spelling | doaj.art-2dec9836ae5f44699ec3bc727a43fc3c2025-03-02T12:45:07ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872021-01-0174202810.17650/2313-805X-2020-7-4-20-28196Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosisI. N. Mikhaylova0N. M. Treshalina1I. Zh. Shubina2I. V. Manina3M. V. Kiselevsky4A. N. Lukashev5N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaInstitute of Allergology and Clinical ImmunologyN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaResearch Institute of Medical Parasitology, Tropical and Vector-borne Diseases named after E. I. Marcinovsky, I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaImatinib mesilate is a well-known antitumor target inhibitor of protein tyrosine kinase, which is effective in different cancer types expressing Bcr / Abl and, in particular, in hemoblastosis. A higher interest to imatinib during the COVID-19 epidemic is explained by the fact that cancer patients are one of the COVID-19 risk groups. Moreover, imatinib target mechanism of action, which is effective in cancer, can have a high potential against the most severe COVID-19 complication such as the disease associated pulmonary fibrosis. COVID-19 associated interstitial pulmonary fibrosis develops as an autoimmune process caused by systemic inflammation with atypical (idiopathic) pneumonia resulting from acute respiratory distress syndrome with the tyrosine kinase mechanism of signaling pathway activation and cellular response. Experi-mental and clinical results showing antifibrotic and dose-related antithrombotic imatinib effect demonstrate perspective use of this antitumor agent to correct COVID-19 associated pneumonia causing a high death rate of patients with COVID-19.The review presents literature data of 2001–2020 discussing pathologic genetic and clinical characteristics of the fibrosis which exacerbates COVID-19 pneumonia in adults. The sequence of the disease processes demonstrates that disease progression with the decreasing oxygen saturation in the peripheral blood intensifies local thrombosis in the lungs. As a result, hypoxia is developing, which is difficult to control and can cause lethal outcome in severe cases. Yet, the conventional antifibrotic and thrombolytic agents can only partially control the process of pneumofibrosis including that of cancer patients. The approximate antifibrotic dose of imatinib 400 mg / day is therapeutic for oncopatho-logy. The antitumor drug registered in many countries and well described side effects and contraindications needs no long-term registration studies for a new indication, therefore, it may be easily prepared for clinical testing.https://umo.abvpress.ru/jour/article/view/300antitumor drugimatinib mesylatetyrosine protein kinasepneumofibrosiscovid-19 |
| spellingShingle | I. N. Mikhaylova N. M. Treshalina I. Zh. Shubina I. V. Manina M. V. Kiselevsky A. N. Lukashev Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis Успехи молекулярной онкологии antitumor drug imatinib mesylate tyrosine protein kinase pneumofibrosis covid-19 |
| title | Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis |
| title_full | Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis |
| title_fullStr | Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis |
| title_full_unstemmed | Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis |
| title_short | Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis |
| title_sort | antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for covid 19 associated pulmonary fibrosis |
| topic | antitumor drug imatinib mesylate tyrosine protein kinase pneumofibrosis covid-19 |
| url | https://umo.abvpress.ru/jour/article/view/300 |
| work_keys_str_mv | AT inmikhaylova antitumorproteinkinaseinhibitorimatinibmayberegardedasapotentialcorrectingagentforcovid19associatedpulmonaryfibrosis AT nmtreshalina antitumorproteinkinaseinhibitorimatinibmayberegardedasapotentialcorrectingagentforcovid19associatedpulmonaryfibrosis AT izhshubina antitumorproteinkinaseinhibitorimatinibmayberegardedasapotentialcorrectingagentforcovid19associatedpulmonaryfibrosis AT ivmanina antitumorproteinkinaseinhibitorimatinibmayberegardedasapotentialcorrectingagentforcovid19associatedpulmonaryfibrosis AT mvkiselevsky antitumorproteinkinaseinhibitorimatinibmayberegardedasapotentialcorrectingagentforcovid19associatedpulmonaryfibrosis AT anlukashev antitumorproteinkinaseinhibitorimatinibmayberegardedasapotentialcorrectingagentforcovid19associatedpulmonaryfibrosis |